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Örebro, SwedenAbstract Plasma cholesterol and triglyceride (TG)
levels are twice as high in hibernating brown bears
(Ursus arctos) than healthy humans. Yet, bears display
no signs of early stage atherosclerosis development
when adult. To explore this apparent paradox, we
analyzed plasma lipoproteins from the same 10 bears
in winter (hibernation) and summer using size
exclusion chromatography, ultracentrifugation, and
electrophoresis. LDL binding to arterial pro-
teoglycans (PGs) and plasma cholesterol efflux ca-
pacity (CEC) were also evaluated. The data collected
and analyzed from bears were also compared with
those from healthy humans. In bears, the cholesterol
ester, unesterified cholesterol, TG, and phospholipid
contents of VLDL and LDL were higher in winter
than in summer. The percentage lipid composition of
LDL differed between bears and humans but did not
change seasonally in bears. Bear LDL was larger,
richer in TGs, showed prebeta electrophoretic
mobility, and had 5–10 times lower binding to arterial
PGs than human LDL. Finally, plasma CEC was
higher in bears than in humans, especially the HDL
fraction when mediated by ABCA1. These results
suggest that in brown bears the absence of early
atherogenesis is likely associated with a lower affin-
ity of LDL for arterial PGs and an elevated CEC of
bear plasma.
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This is an open access article under the CC BY license (http://creativecommons.org/licThe plasma lipoproteins of many mammalian species
can be separated into corresponding classes of chylo-
microns (CMs), VLDL, LDL, and HDL (1). The lipopro-
teins in each class share similar density ranges but have
species-specific lipid and apolipoprotein composition.
Furthermore, the association between plasma lipid li-
poprotein levels and the susceptibility to atherosclerosis
development vary within a species (1). Several species of
the genus Ursus, which hibernate during winter, have
levels of plasma total cholesterol (TC), triglycerides
(TGs), and phospholipids (PLs) that are much higher
than those found in healthy humans (2–5). Interestingly,
European brown bears (Ursus arctos), which have high
TC, LDL-C, and TG, apparently do not develop
atherosclerosis (6). In bears, plasma lipids circulate as
lipoproteins with densities similar to those of human
VLDL, LDL, and HDL (2–5). Paradoxically, the plasma
levels of lipids and lipoproteins in brown bears are
higher in hibernation (fasting) than when these animals
are active and have access to food (2–4, 6). The field and
laboratory activities of the Scandinavian Brown Bear
Research Project (https://bearproject.info) have pro-
vided access to blood and tissue samples taken from the
same animals during hibernation in winter (February)
and when active in summer (June). Previous studies
from this project documented the pronounced meta-
bolic differences between winter and summer and
provided valuable translational information for the
relation of these changes with human disease (2). Most
evident are differences in metabolic parameters related
to energy balance, hematological adaptation, endocrine
status, kidney function, protein synthesis, proteinJ. Lipid Res. (2021) 62 100065 1
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degradation, and plasma lipids (2, 5, 6). High plasma
levels of TC, TG, LDL-C, HDL-C, and circulating lipases
are associated with hibernation in both black and
brown bears (3, 4, 6). Interestingly, histopathological
examination of the descending coronary artery and
aortic arches of 12 adult free-ranging bears revealed no
sign of foam cell infiltration, fatty streaks, or late le-
sions. Arterial specimens from bears had similar
morphology to muscular arteries as found in non-
atherosclerotic healthy humans (6).
The lack of association between high plasma lipid
levels and early stage atherosclerosis development in
free-ranging brown bears is poorly understood, despite
its translational potential to the human conditions. In
the present study, we examined the lipoprotein
composition and functions from the same free-ranging
Swedish brown bears during hibernation and in their
active state and compared them with those of appar-
ently healthy humans. Apolipoprotein B (apoB)-con-
taining lipoproteins (VLDL, remnants, LDL, and
lipoprotein (a)), which enter the arterial intima can
become bound to proteoglycans (PGs) in the extracel-
lular matrix. This process initiates plaque formation as
described in the “response to retention” hypothesis of early
atherogenesis (7, 8). Conversely, apolipoprotein AI
(apoAI)-containing lipoprotein (HDL) seem to have
antiatherogenic properties by promoting cholesterol
efflux from peripheral cells [cholesterol efflux capac-
ity (CEC)] (9).
In the present study, we report on the lipoprotein
composition and two functional properties that appear
to modulate early atherogenesis in humans and pre-
clinical mammalian models: the association of LDL with
arterial PGs and the capacity of plasma to remove
cholesterol from extrahepatic cells (CEC).MATERIALS AND METHODS
Animals
Bear capture, anesthesia, and sampling procedures have
been described previously (5, 6, 10). In summary, to trace their
movement, the bears were equipped with collars with a Global
Positioning System collars and very high frequency trans-
mitter implants. A team from the Scandinavia Brown Bear
Research Project collected samples from the same subadult
Swedish brown bears twice a year, during hibernation
(February 2011 and 2012) and the active state (June 2011 and
2012). All capture and handling protocols were approved by
the Swedish Ethical Committee on Animal Research (appli-
cation numbers C212/9 and C47/9) and the Swedish Envi-
ronmental Protection Agency. All captures were carried out
in Dalarna and Gävleborg counties, south-central Sweden.
Blood was drawn from the anesthetized animal and collected
in tubes containing EDTA as anticoagulant. The coded blood
samples were kept in refrigeration (1–2 h) during rapid
transport (helicopter) to the field laboratory, where plasma
was prepared by centrifugation (2,000 g, 4◦C, 10 min). EDTA
plasma samples were frozen and shipped on dry ice to our
laboratory, where they were stored at −80◦C.2 J. Lipid Res. (2021) 62 100065Materials and reagents
RPMI medium, high glucose DMEM, MEM, trypsin-EDTA,
gentamicin, and penicillin-streptomycin were purchased
from Thermo Fisher Scientific Europe BV, The Netherlands
(Stockholm, Sweden). Tissue culture flasks, plates, scrapers,
and tubes were purchased from Thermo Fisher Scientific
Europe BV, The Netherlands (Stockholm, Sweden) or Falcon
(Lincoln, NY). Polyethylene glycol solution, FBS, ACAT in-
hibitor Sandoz 58-035, DMSO, BSA, and 8-(4-
chlorophenylthio)-cAMP salt were purchased from Sigma-
Aldrich® (Stockholm, Sweden). [1,2-3H(N)]-cholesterol and
Ultima Gold™ were purchased from PerkinElmer® (Upp-
lands Väsby, Sweden). Block lipid transporter 1 was purchased
from ChemBridge Corporation (San Diego, CA). Human re-
combinant apoAI was purchased from tebu-bio (Le Perray-
en-Yvelines, France).
Serum samples (n = 14) were randomly selected from a
large cohort of healthy subjects enrolled in the Swedish
physical activity and fitness cohort study ((11); ethical
permission: EPN Umeå, Dnr 09-082M). One serum pool from
eight healthy volunteers, who signed the informed consent
form in adherence to the Declaration of Helsinki, was pre-
pared at the Division of Clinical Chemistry, Department of
Laboratory Medicine, Karolinska Institutet at Huddinge
University Hospital, Stockholm, Sweden. Human samples
were employed for comparative purpose.
Cell lines and culture
J774A.1 murine macrophages were purchased from LGC
Standards (Wesel, Germany). Fu5AH rat hepatoma cells were
a gift from Prof Franco Bernini (Department of Food and
Drug, University of Parma, Italy). Cell lines were cultured in
RPMI medium or high glucose DMEM, respectively, at 37◦C in
a 5% CO2 atmosphere. All cell media were supplemented with
10% FBS and gentamicin (50 μg/ml).
Plasma lipoproteins
Lipoproteins were separated from 2.5 μl of individual
plasma samples by size exclusion chromatography, using a
Superose 6 PC 3.2/300 column (GE Healthcare Bio-Sciences
AB, Uppsala, Sweden). Lipoproteins were eluted as a frac-
tion appearing in the exclusion volume of the sepharose
column that contained CMs (if present) together with VLDL
(named CM/VLDL), then LDL, and last HDL. TG, TC, unes-
terified cholesterol (UC), and PL concentrations were calcu-
lated after integration of the individual chromatograms (12,
13), generated by the enzymatic-colorimetric reaction with
the respective kits: cholesterol oxidase phenol 4-
aminoantipyrine peroxidase, glycerol phosphate oxidase-p-
aminophenazone (Roche Diagnostics, Mannheim, Germany),
and free cholesterol E, PL C (FujiFilm Wako Diagnostics,
Mountain View, CA). The amount of esterified cholesterol
was calculated by subtracting the UC from the TC. When
cholesterol esters (CEs) were expressed in milligrams per
deciliter, the values were multiplied for 1.67 in order to ac-
count for the fatty acid moiety.
Lipoproteins were also separated by sequential density ul-
tracentrifugation in deuterium oxide-sucrose solutions (14).
The lipoprotein fractions were resuspended in a buffer vol-
ume equal to the original sample volume. This procedure is
suitable to small plasma volumes and allows for rapid analysis
of the separated lipoprotein classes in electrophoretic and PG
binding experiments. This method avoids interference of
high salt concentrations, as would be the case using classic
potassium bromide ultracentrifugation (14). Native electro-
phoresis of lipoprotein fractions was conducted with semi-
automated equipment, and lipoproteins were stained by
Sudan black (Sebia, Paris, France), by loading 10 μl of CM/
VLDL/remnants (d = 1.006–1.019 g/ml), LDL (d =
1.019–1.063 g/ml), or HDL (d = 1.063–1.210 g/ml) into Hydragel
7 LIPO + lipoprotein (a) wells (Sebia, Paris, France). SDS-
denaturing polyacrylamide gel electrophoresis of isolated li-
poproteins as previously described (14) was used with the
following modifications: 10 μl of Spectra Multicolor Broad
Range Protein Ladder, HiMark Prestained Protein Ladder, or
Spectra Multicolor Low Range Protein Ladder (Thermo
Fisher Scientific Europe BV, The Netherlands) or 10–20 μl
sample were added to each well of NuPAGE 4–12% Bis-Tris,
Nupage 3–8% Tris-Acetate, or Novex 10% Tricine Protein
Gel (Thermo Fisher Scientific Europe BV, The Netherlands)
and run for about 50 min at a constant 200 V. Protein staining
was performed with SimplyBlue Safe Stain (Thermo Fisher
Scientific Europe BV, The Netherlands) and 20% NaCl solu-
tion, according to the manufacturer's protocol. Gel pictures
were taken by Li-Cor Odissey Fc Imager and Image Studio 3.1
(LI-COR Biosciences – GmbH, Bad Homburg vor der Höhe,
Germany) at 700 nm and 10 min exposure.Ex vivo binding of LDL to arterial PGs
This analysis was performed as previously described (15). In
brief, human aortic PGs were isolated from the intima media
of human aortas, and glycosaminoglycans from the PGs were
quantified as markers of PG amounts. The wells of poly-
styrene 96-well plates were coated with 100 μl of PGs (50 μg/
ml in PBS) by incubation at 4◦C overnight. Wells were blocked
with 1% BSA in PBS for 1 h at 37◦C. Wells without PGs served
as controls. To measure lipoprotein binding to the immobi-
lized PGs, 1 μl of heavy water/sucrose-isolated LDL was added
to the wells in a buffer containing 140 mmol/l NaCl, 2 mmol/l
MgCl2, 5 mmol/l CaCl2, and 10 mmol/l MES, pH 5.5, and
incubated for 1 h at 37◦C. The wells were then washed with
10 mmol/l MES, 50 mmol/l NaCl, pH 5.5, and the amount of
bound cholesterol was determined using the Amplex Red
Cholesterol Kit (Thermo Fisher Scientific Europe BV, The
Netherlands). The results are expressed as amount (micro-
moles) of bound-LDL-C per millimoles LDL-C added to the
PG-coated wells.Cholesterol efflux capacity
Plasma specimens were thawed no more than twice on ice,
and apoB-depleted serum was prepared (16). Aliquots were
stored at −80◦C. Cholesterol efflux experiments were per-
formed as previously described (13) to evaluate CEC of both
whole and apoB-depleted serum. Briefly, cells were incubated
for 24 h with medium containing 1% FBS, [1,2-3H(N)]-choles-
terol, and Sandoz 58-035 (2 μCi/ml). Cells were then incubated
for 18 h with medium plus 0.2% BSA and Sandoz 58-035
(2 μCi/ml), adding compounds when appropriate. After this
incubation, a set of cells were harvested with NaOH (1 mol/l)
and counted by liquid scintillation. These cells provided
baseline (time 0) values for total [1,2-3H(N)]-cholesterol con-
tent. The remaining cells were incubated with 1% (v/v) serum
or 1.4% apoB-depleted serum (v/v) added to MEM for 4 h. Cell
media were filtered to remove floating cells, and radioactivity
in the supernatant was determined by liquid scintillation
counting. Cholesterol efflux was calculated as follows: (cpm in
medium at 4 h/cpm at time 0) × 100. J774.A1 cells cultured
under basal conditions were used to evaluate the aqueousLipoproteindiffusion (AD). The ABCA1-mediated cholesterol efflux was
the difference between the cholesterol efflux measured in
J774 cells incubated with 8-(4-chlorophenylthio)-cAMP
(0.3 mmol/l) and the cholesterol efflux measured in J774 cells
cultured under basal conditions. The cholesterol efflux via
scavenger receptor class B type I (SR-BI) was the difference
between the cholesterol effluxes measured in Fu5AH cells
cultured under basal conditions and in Fu5AH cells incubated
with block lipid transporter 1 (10 μmol/l).Plasma LCAT and cholesteryl ester transfer protein
activity assay
Plasma LCAT activity was measured using an exogenous
standardized substrate as previously described (17). Briefly, the
substrate was a reconstituted HDL made of apoAI, palmitoy-
loleylphosphatidylcholine and cholesterol at a weight ratio of
1:2.17:0.11 (corresponding to a molar ratio of 1:80:8), prepared
by the cholate dialysis technique. Plasma and reconstituted
HDL were mixed at a 1:10 volume ratio and incubated for 1 h
at 37◦C. UC was measured before and after the incubation by
a standard enzymatic assay in the absence of cholesterol
esterase. Absorbance at 510 nm was measured with a Synergy
H1 multimode reader (BioTek Instruments, Inc., Winooski,
VT).
Plasma cholesteryl ester transfer protein (CETP) activity
was measured in 1.5 μl of sample using CETP Activity Assay
Kit (Merck KGaA, Darmstadt, Germany), according to the
manufacturer's instructions. Fluorescence was measured
kinetically by Infinite F500 microplate reader (Tecan Trading
AG, Switzerland).Statistical analysis
Continuous variables are presented as median (10th–90th
percentile). Absolute numbers or percentages are summarized
as categorical variables. Statistical analysis was performed
using Statistica software (TIBCO, CA). Differences between
the bears in winter to summer were determined by Wilcoxon
signed rank test. When comparing humans with bears, the
Kruskal-Wallis ANOVA was used followed by a multiple
comparison post hoc test. For correlations, statistics were
calculated by Spearman's rank R. Graphs were prepared using
GraphPad Prism (GraphPad Software Inc., CA), and figures
were prepared by Adobe Illustrator (Adobe Systems Inc., CA).RESULTS
Lipoprotein profiles and lipoprotein compositions
The plasma TC, TG, UC, and PL concentrations for
bears in winter and summer and for human controls
are presented in Fig. 1. In winter, when fasting, bears
had more than 50% higher plasma levels of TC, UC, PL,
and TG 30% higher, compared with summer. When
compared with human healthy controls, all bear plasma
lipid classes evaluated were higher only during hiber-
nation (Fig. 1A–C), except for PL levels that were also
higher in the summer (Fig. 1D). The lipid lipoprotein
profiles by size exclusion chromatography (Fig. 2A)
showed that TC in bears was carried mainly in the li-
poprotein fraction corresponding to the human CM/
VLDL and LDL in the winter (like in humans), whereas























































































Fig. 1. Plasma total lipid concentrations. Blood samples from
n = 10 bears (black triangles) were taken during winter
(February and March) and summer (June). N = 14 human serum
samples (white circles) were run for comparative purposes.
Plasma lipoproteins were separated by size exclusion chroma-
tography (12, 13), and the TC (A) and UC (C), TGs (B), and PLs
(D) concentrations were determined by a system allowing online
detection. Data are plotted as individual values. Comparison
between bears in winter versus summer was performed by
Wilcoxon matched-pairs signed rank test, whereas comparison
between human and bear in winter or bear in summer was
done by Kruskal-Wallis ANOVA (at least P < 0.05) followed by
multiple comparison test. Significances are indicated as follows:
**P < 0.01, ***P < 0.001.carried in HDL-sized particles. During the winter, TGs
in bears were transported, unexpectedly, mostly in LDL
(Fig. 2B). Figure 2C shows that the high content of UC
in winter was distributed between CM/VLDL and LDL,4 J. Lipid Res. (2021) 62 100065but in the summer, the UC profile of bears was similar
to that observed in humans. The elevated PL content of
bears in winter (Fig. 2D) was similarly distributed in
CM/VLDL, LDL, and HDL, whereas in the summer, the
PLs were more prominent in LDL and HDL, similar to
the distribution present in humans. As shown by their
respective earlier elution times (Fig. 2), bear LDLs were
larger than human LDLs.
Table 1 shows the concentration of CE, UC, TG, and
PL in the different lipoprotein classes with the respec-
tive percentage of lipid composition. During hiberna-
tion, the major lipid classes in CM/VLDL increased
more than 5–10 times above the summer levels in all 10
animals examined. Conversely, the increase of individ-
ual lipids in the LDL particles from hibernating bears
was only one to two times higher, when compared with
samples from the active summer period (Table 1). CE,
TG, and PL levels of bear HDL did not differ between
summer and winter. However, the bears in summer
showed higher HDL-UC than in the winter (Table 1).
In bears, the percentage of lipid composition of
CM/VLDL, LDL, and HDL was not different during
hibernation compared with the active states (Table 1).
However, in winter, the bears had higher LDL-UC than
in the summer. Major differences in both lipid con-
centration and percentage composition were observed
between humans and bears (Table 1). Most noticeable
were the higher levels of CE, TG, UC, and PL in the
bear LDL during winter compared with humans. Also,
bear LDLs were proportionally richer in TG and
poorer in CE.
Plasma LCAT and CETP activity assay
Plasma LCAT activity seemed to be lower in bears
than in humans, with a tendency to increase in from
winter to summer (Table 2). These results were paral-
leled by a decreased plasma and HDL UC/TC ratio
(supplemental Fig. S1). Moreover, we could not detect
any CETP activity in the plasma from brown bears both
in the winter and summer (supplemental Fig. S2).
Electrophoretic properties of winter and summer
lipoproteins
Native agarose electrophoresis of isolated bear lipo-
proteins revealed no major differences in electropho-
retic mobility between winter and summer (Fig. 3).
However, it should be noted that CM/VLDL/remnants
(d = 1.006–1.019 g/ml) and LDL (d = 1.019–1.063 g/ml)
share similar electrophoretic prebeta mobility (Fig. 3A,
B), and both classes were much more anodic than hu-
man LDL (prebeta vs. beta). On the other hand, human
and bear HDL (d = 1.063–1.21 g/ml) showed similar
electrophoretic mobility (Fig. 3C). Thus, it appears that
the brown bears had little or no beta lipoproteins. These
electrophoretic properties were observed in all 10 bears.
We also used SDS-polyacrylamide gel gradient elec-
trophoresis to examine the most abundant apolipo-













































































Fig. 2. Plasma lipid lipoprotein chromatograms. Blood sam-
ples from n = 10 bears were taken during winter (February and
March; black lines) and summer (June; red lines). N = 14 human
serum samples (blue lines) were run for comparative purposes.
Plasma lipoproteins were separated from 2.5 μl individual
sample, by size exclusion chromatography (12, 13), and the in-
dividual chromatograms were generated by an enzymatic
colorimetric reaction with the respective kits for TC (A) and UC
(C), TGs (B), and PLs (E). Data are plotted as average
Lipoproteinremnants (Fig. 3D, F, H) seem to be particles containing
apoB100, apoAI, and apolipoprotein E (apoE) as the
most abundant apolipoproteins. This was also observed
for the LDL fractions (Fig. 3E, G, I). Interestingly, and
differently from human lipoproteins, we found that
the bear apoB100-containing particles seem to be more
enriched in apoAI than apoE (Fig. 3H, I).
LDL binding to human arterial PGs
The binding of isolated LDL to human arterial PGs
was measured ex vivo. Although CE and UC content in
bear LDL is higher in winter than in summer (Table 1),
Fig. 4A shows that the winter LDL binds significantly
less to human arterial PGs. These differences were
observed even when adjusting the values of binding of
LDL to PGs for the amount of LDL-TC added to the
wells (Fig. 4B). Interestingly, both the winter and sum-
mer LDL from the bears bound 5 to 10 times less to the
arterial PGs than the human LDL tested in the same
analytical runs (Fig. 4).
Plasma and HDL CEC
CEC was measured in whole plasma and apoB-
depleted plasma, and the latter was lower in all the
cholesterol efflux pathways studied (Fig. 5). Plasma
CEC by AD (Fig. 5A) was almost double in bears
compared with humans, but it did not differ between
the summer and winter bear samples. The apoB-
depleted plasma CEC (Fig. 5B) was higher in humans
than in bears, but there was no difference in the CEC in
the apoB-depleted plasma of hibernating and active
bears. Plasma CEC via the SR-BI pathway was twice as
high in bears compared with humans (Fig. 5C). Plasma
CEC by SR-BI pathway was higher in summer than in
winter, but this difference was lost when we evaluated
the CEC using apoB-depleted serum (Fig. 5D). Human
apoB-depleted plasma seems to have lower capacity to
accept cholesterol via SR-BI than the bear apoB-
depleted plasma specimen in summer (Fig. 5D). We
also studied CEC via ABCA1, which was lower in serum
from humans compared with bears in both summer
and winter (Fig. 5E). Plasma CEC via ABCA1 from bears
in summer decreased compared with the CEC in winter
(Fig. 5E). When looking at apoB-depleted plasma CEC
by this transporter, there were no differences between
bears in summer and winter, but bears showed higher
CEC than humans (Fig. 5F).
DISCUSSION
We believe that our results provide for the first time
a mechanistic explanation that can contribute to the
observed resistance to early atherogenesis of free-
ranging brown bears, despite their high circulating
levels of cholesterol and TG, especially duringchromatogram for each group (solid line) ± standard error of
the mean (shadow around the solid line).
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Human (n = 14)
Bear
Human (n = 14)
Bear
Human (n = 14)Winter (n = 10) Summer (n = 10) Winter (n = 10) Summer (n = 10) Winter (n = 10) Summer (n = 10)
CE mmol/L 0.85 (0.39–1.28)** 0.05 (0.02–0.25)a 0.67 (0.31–1.16) 4.64 (2.28–5.92)**,b 1.40 (1.05–2.41) 2.15 (1.54–2.96) 2.84 (1.80–5.00)a 3.31 (2.20–4.47)a 1.08 (0.67–1.89)
CE mg/dL 55.18 (25.38–82.82)** 3.13 (1.36–16.7)a 43.46 (20.15–74.72) 299.81 (147.14–382.40)**,b 90.25 (67.94–155.67) 130.09 (99.19–178.88) 183.44 (115.95–321.41)a 213.43 (140.03–288.76)a 68.61 (43.53–112.04)
% weight 17 (7–20)b 11 (5–36)c 25 (13–36) 33 (23–41)c 23 (18–34)a 48 (46–52) 48 (39–59)a 44 (40–50)b 36 (31–41)
TG mmol/L 1.63 (1.11–2.12)** 0.16 (0.05–0.36)c 0.95 (0.31–2.36) 3.71 (2.15–4.93)**,a 1.65 (1.32–2.14)c 0.39 (0.29–0.59) 0.15 (0.12–0.18)a 0.12 (0.12–0.23)c 0.22 (0.19–0.34)
TG mg/dL 144.63 (97.87–187.7)** 14.30 (4.69–32.16)c 84.14 (27.45–209.02) 328.55 (190.69–437.09)**,a 146.62 (117.13–189.10)c 34.54 (25.69–52.26) 13.33 (10.45–16.34)a 13.99 (10.76–20.15)c 19.92 (16.82–30.11)
% weight 40 (36–45) 42 (20–73) 47 (29–63) 38 (32–41)a 37 (28–47)a 12 (10–20) 4 (2–5)a 3 (2–6)a 10 (7–18)
UC mmol/L 0.94 (0.61–1.30)**,b 0.06 (0.02–0.12)c 0.37 (0.15–0.66) 1.48 (1.05–2.37)**,a 0.79 (0.53–1.11) 0.77 (0.60–0.95) 0.26 (0.19–0.40)* 0.50 (0.32–0.66) 0.33 (0.21–0.57)
UC mg/dL 36.43 (23.76–50.31)**,b 1.89 (0.85–4.53)c 14.25 (5.61–25.41) 57.15 (40.70–91.74)**,a 30.30 (20.50–42.89) 29.64 (23.32–36.62) 10.03 (7.44–15.45)* 19.06 (12.45–25.64) 12.94 (7.93–22.20)
% weight 9 (8–13)*,c 8 (3–11) 8 (6–9) 7 (6–10)a 7 (6–9)c 11 (10–12) 3 (2–3)**,a 4 (3–4)b 7 (6–8)
PL mmol/L 1.65 (1.17–1.96)**,c 0.14 (0.05–0.21)b 0.45 (0.22–0.63) 2.57 (1.85–3.43)**,a 1.58 (1.17–2.01)b 0.97 (0.66–1.19) 2.19 (1.90–3.28)c 2.95 (2.42–3.97)a 1.15 (0.71–1.67)
PL mg/mL 127.5 (90.62–151.82)**,c 10.9 (4.17–16.35)b 34.76 (16.70–48.87) 198.98 (142.62–264.98)**,a 122.10 (90.23–155.03)b 75.23 (51.34–92.24) 169.25 (146.32–253.65)c 227.82 (187.08–306.84)a 88.76 (55.13–129.43)
% 32 (28–39)a 28 (18–42)b 18 (13–24) 23 (20–31) ** 29 (26–35) 29 (22–31) 46 (36–54) 50 (45–54)b 46 (40–49)
Blood samples from bears were taken during winter (hibernation, February, March) and summer (June, free-ranging). N = 14 human serum samples were run for comparative purposes.
Plasma lipoproteins were separated by size-exclusion chromatography, and the total cholesterol (TC) and unesterified cholesterol (UC), triglyceride (TG), and phospholipid (PL) concentrations
were determined by a system allowing on-line detection. Cholesterol ester (CE) concentration was calculated as the difference between TC and UC. When the CE concentration is expressed in
mg/dL, the value has been multiplied for 1.67 to account for the fatty acid moiety. Data are presented as the median (10th–90th percentile) and indicate the concentration (mmoL/L or mg/dL)
of each lipid species or their % weight composition within the lipoprotein particles. Comparison between bears in winter and bears in summer was performed by Wilcoxon matched pairs























Human (n = 14) 21.56 (6.3–32.0)
Bdl, below detection limit.
Blood samples from n = 7 bears were taken during winter
(February and March) and summer (June) and plasma prepared by
centrifugation. N = 14 human serum samples were run for
comparative purposes. LCAT activity was detected as previously
described (17). Data for human are given as median (range).hibernation (5, 6). We found that LDL and HDL circu-
lating in brown bears have functional and structural
properties that could reduce their atherogenicity and
protect them from vascular lipid infiltration and in-
juries. Bear LDL in the winter contained higher levels
of TC and TG than in summer and when compared
with humans (Fig. 1; Table 1). However, brown bear LDL
showed a lower percentage content of CE than human
LDL. Also, LDLs circulating in brown bears were
approximately 2-fold richer in TG than the human
LDLs. Thus, bear LDL, in both winter and summer, may
deliver per particle less cholesterol to the arterial wall
than human LDL. Moreover, bear LDL in both winter
and summer were larger than human LDL (Fig. 2). This
could be a consequence of their enrichment in TG
(about 40% of total lipid cargo). In humans, the TG
content carried by both small and large LDL separated
by ultracentrifugation is only about 4–7% of the total
lipid composition (18, 19). In our cohort of healthy
humans, TG in LDL accounted for 2–5% of the total
lipids. LCAT (20), an HDL-associated enzyme, catalyses
the transfer of a fatty acid from PLs to UC resulting in
the formation of CEs, which then move from the sur-
face of the HDL particle to the core. The newly formed
mature HDL can become the substrate for the CETP,
which in turn affects TG-rich lipoprotein metabolism.
Thus, we quantified brown bear plasma LCAT activity
and found increased activity in summer compared with
winter (Table 2). Those results were supported by a
decrease in summer of the ratio between plasma and
HDL UC/TC (supplemental Fig. S1), which is known, at
least in humans, to be associated with plasma LCAT
activity (21). Moreover, plasma LCAT seems to be lower
in brown bears than in humans (Table 2). By
exchanging TG in apoB-containing lipoproteins for CE
in HDL, CETP is supposed to increase the cholesterol
content of VLDL and LDL and thus reduce their TG
cargo (22). In the present study, we could not detect any
CETP activity in the plasma from bears in the winter or
in the summer (supplemental Fig. S2). Taken together,
these results provide one possible explanation for theLipoproteinTG enrichment of apoB-containing particles in these
bears. Interestingly, in humans, large LDL particles are
less associated with atherogenesis than small LDL, and
several properties of LDL particles can explain this
reduced atherogenicity (18, 19, 23, 24). Small LDL par-
ticles have a higher affinity for arterial intima PGs and
can be more efficiently retained in the subendothelial
space (7, 8, 18, 23). In addition, they appear to be more
sensitive than large LDL to oxidative modifications and
are more efficiently taken up by cultured human
macrophages (7, 8, 23).
Retention of apoB100-containing lipoproteins,
mainly LDL, within the arterial intima PGs appears to
be the initial step leading to cholesterol accumulation,
which triggers the inflammatory cascade and causes
atherosclerosis (7, 8). The binding of human apoB100
lipoproteins to arterial PGs is mediated by specific se-
quences rich in arginine and lysine that have been
identified ex vivo and animal models (25, 26). The
amino acid sequence of brown bear apoB100 is more
than 76% homologous with the human sequence over
the full-length protein (Uniprot accession: P04114 for
Homo sapiens and A0A3Q7Y8U4 for Ursus arctos; NCBI
RefSeq accession: NP_000375.3 for Homo sapiens and
XP_026375362.1 for Ursus arctos, see supplemental
Tables S1 and S2 and supplemental Fig. S3). In
humans, the apoB100 amino sequence containing the
main arterial PG binding regions (amino acids
3,121–3,180 and 3,361–3,420) are polar segments with an
excess of six positively charged lysine and arginine
residues (7, 8, 25, 27–30). These segments, located
toward the C-terminal region of apoB100, are hydro-
philic and surface exposed in human LDL (31), and this
is also probable in the bear apoB100-containing lipo-
proteins. However, the same segments in Ursus arctus
have only one excess positive charge (supplemental Fig.
S4). Thus, apoB100-containing lipoproteins in bears
should have a lower affinity for arterial PGs than the
human LDL. This is supported by our results from the
ex vivo assay of LDL-PG binding (Fig. 4). Importantly, it
should be noted that the LDL of patients with clinical
atherosclerosis (e.g., dyslipidemic patients with insulin
resistance) ex vivo show a higher binding to arterial
PGs than healthy controls (7, 8, 27, 32). For the first time,
we showed that LDL in brown bears during winter
displayed a lower binding than LDL in the summer,
despite their higher CE and UC contents. More impor-
tantly, we demonstrated that LDLs from brown bears
have much lower PG binding capacity than humans,
regardless of the hibernating or active state. Liu et al.
(28) in a population study concluded that polar bears
(Ursus maritimus) diverged as a different species from
brown bears only 400,000 years ago likely because of
the extreme environmental pressures. Polar bears also
have very high plasma levels of apoB-containing lipo-
proteins that appear to be a response to their very high
fat diet all year around. In view of our findings, it
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Fig. 3. Native and denaturing gel electrophoresis of lipoproteins. Blood samples from n = 10 bears were taken during winter
(February and March) and summer (June). N = 14 human serum samples or a human reference serum pool (n = 8) were run for
comparative purposes. Plasma lipoproteins were separated by sequential density ultracentrifugation in deuterium oxide-sucrose
solutions (14). For native gel electrophoresis, 10 μl of CM/VLDL/remnants (d = 1.006–1.019 g/ml; (A) LDL (d = 1.019–1.063 g/ml;
(B) or HDL (d = 1.063–1.210 g/ml; (C) were loaded into an agarose gel and neutral lipids were stained by Sudan black. For denaturing
gel electrophoresis: 20 μl of isolated CM/VLDL/remnants were loaded into a 4–12% Bis-Tris (D), 3–8% Tris-acetate (F), or 10% tricine
gel well (H). About 20 μl of isolated LDL were loaded into a 4–12% Bis-Tris (E), 3–8% Tris-acetate (G), or 10% tricine (I) gel well.
Proteins were stained by Coomassie blue. h, lipoprotein pool from apparently healthy humans (n = 8); S, bears sampled in the
summer; W, bears sampled in the winter.




































































Fig. 4. Binding of isolated LDL from brown bears to human
arterial PGs. Blood samples from n = 10 bears (black triangles)
were taken during winter (February and March) and summer
(June). N = 14 human serum samples (white circles) were run
for comparative purposes. Plasma lipoproteins were separated
by sequential density ultracentrifugation in deuterium oxide-
sucrose solutions (14). About 1 μl of isolated LDL (d =
1.019–1.063 g/ml) was tested to measure lipoprotein capacity to
bind to human arterial PGs, isolated from human aortas, and
plated in a 96-well plate. Results are expressed as micromoles of
bound TC to the well (A) or as micromole of bound TC to the
well divided by millimoles of LDL-TC added to the well (B).
Data are plotted as individual values. Comparison between
bears in winter versus summer was performed by Wilcoxon
matched-pairs signed rank test, whereas comparison between
humans and bears in winter or bears in summer was done by
Kruskal-Wallis ANOVA (at least P < 0.05) followed by a mul-
tiple comparison test. Significances are indicated as follows: **P




























































































Fig. 5. Plasma and HDL CEC. Cells were radiolabeled with
[3H]-cholesterol for 24 h, equilibrated in a BSA-containing
medium for 18 h, and exposed for 4 h to 1% (v/v) whole
plasma (left panels) or 1.4% (v/v) apoB-depleted plasma (right
panels). AD was assessed in J774A.1 cells, cultured under basal
conditions (A, B); SR-BI-mediated efflux (C, D) was the differ-
ence between cholesterol efflux measured in Fu5AH cells
cultured under basal conditions and Fu5AH cells incubated
with block lipid transporter 1 (BLT-1). ABCA1-mediated
cholesterol efflux (E, F) was the difference between the
cholesterol efflux measured in J774A.1 cells, incubated with 8-
(4-chlorophenylthio)-cAMP, and the cholesterol efflux
measured in J774A.1 cells cultured under basal conditions.
Blood samples from n = 10 bears (black triangles) were taken
during winter (February and March) and summer (June). N = 14
human serum samples (white circles) were run for comparative
purposes. Data are plotted as individual values. Comparison
between bears in winter versus summer was performed by
Wilcoxon matched-pairs signed rank test, whereas comparison
between human and bears in winter or bears in summer was
done by Kruskal-Wallis ANOVA (at least P < 0.05) followed by a
multiple comparison test. Significances are indicated as follows:
*P < 0.05, **P < 0.01, and ***P < 0.001.properties of polar bears VLDL and LDL and explore if
they also have potentially atheroprotective properties
as in brown bears.
In patients affected by cardiovascular diseases and in
healthy controls, the LDL-C/apoB ratio, the apoB/TG
ratio, and the LDL isoelectric point (i.e., surface charge)
can predict the ex vivo complex formation of LDL with
arterial PGs (LDL-PG affinity) with 70% accuracy (8,
33). Thus, the lower proportion of CE and UC, but
higher proportion of TG, observed in brown bear LDL
can explain their lower PG binding when compared
with human LDL. Moreover, it is shown that human
LDL that forms complexes with the highly negative
sulfated glycosaminoglycans of the arterial PGs re-
quires a beta electrophoretic mobility and a higher
isoelectric point (pI = 5.54). It should be noted that in
the binding assay used, the human VLDL with prebeta
mobility (pI = 5.1) bind very little to arterial PGs at
physiological pH (7, 8, 34). In the present study, we
found that brown bear LDL had a prebeta and not a
beta electrophoretic mobility (Fig. 3). Human LDL has aLipoproteinbeta electrophoretic mobility similar to most
nonhuman models of atherosclerosis (Fig. 3 and (35)).
Indeed, lipoproteins that show agarose electrophoresis
beta mobility, such as human LDL, have a negative
surface charge from −4 to −7 mV, whereas those with
prebeta mobility have a charge from −7 to −10 mV,
such as the LDL of brown bears and human VLDL (35).
The higher negative (or less positive) surface charge of
the bear LDL particles might be caused by the
mentioned differences in the surface-exposed apoB100
segments. Another possible reason for the prebeta
mobility of the brown bear LDL could be the presence
of nonesterified fatty acids bound to the bear LDL
particle surface or dissimilarities in the content ofcomposition and functions: brown bear versus human 9
associated exchangeable apolipoproteins (e.g., apoCIII,
apoAI, and apoE) (35). From the analysis performed in
this study, we are not able to provide any information
regarding the different apoC isoforms bound to the
bear lipoproteins. Nevertheless, we could show (Fig. 3)
that the apoB100-containing particles (1.006 < d < 1.063),
which both in winter and summer contained high levels
of TG, seem to be more enriched in apoAI rather than
ApoE. This apolipoprotein composition was more
evident in the lipoprotein LDL particles with a density
range between 1.019 and 1.063. It is a different condition
than the human one, where apoAI is not associated to
apoB100 but only to apoB48 when the CMs are in the
lymph. Being such TG-rich apoB100-containing parti-
cles and having apoAI instead of apoE, this may lend to
them being recognized to a lesser extent by scavenger
receptors. Moreover, the presence of apoAI seems to
reduce the ability to bind to PGs. Thus, from a lipo-
protein point of view, brown bears seem to resemble
dysbetalipoproteinemia (type III), but the absence of
apoE and apoB48 makes their LDL size/density lipo-
proteins to become not atherogenic (the latter prevents
a condition similar to an ApoE knockout).
The higher proportion of apoAI in bear LDL (d =
1.019–1.063) might also result from the presence of large
HDL-1 in these density fractions. Indeed, the native
agarose gel electrophoresis showed the presence of
α-migrating lipoproteins (Fig. 3B). Moreover, these lipo-
protein density fractions were characterized by an extra
lipoprotein peak, with a size in between that of LDL and
HDL, which was present in bears both in winter and
summer and seems mainly composed of cholesterol and
PLs (supplemental Fig. S5). This extra lipoprotein peak
has been also described in other animal species as a large
apoE-rich HDL (13, 36, 37). Nevertheless, in bears, the
amount of apoE seems to be relatively very small,
whereas the apoAI is predominant.
Cellular cholesterol efflux to HDL is one of the
initial steps in reverse cholesterol transport, and it oc-
curs by several mechanisms. These rely upon different
HDL subclasses that are specific acceptors for individ-
ually identified mechanisms (38, 39): a) AD (which in-
cludes unknown transporters) to mature HDL; b) SR-BI-
mediated efflux to mature HDL; c) ABCG1-mediated
efflux to mature HDL and preβ-HDL; and d) ABCA1-
mediated efflux to apoAI, preβ-HDL, and small HDL
particles (16, 40–42). To our knowledge, this is the first
time that CEC as metric of HDL function has been
measured in brown bears and compared with that in
humans with the same methods. The cell models used
in the efflux assay are heterologous and may interact
differently with plasma lipoprotein than with bear
extrahepatic cells. Nevertheless, all the serum speci-
mens were tested in the same culture conditions and
well-established cell models employed for measuring
CEC both in human and preclinical studies (13, 16, 43).
Hence, we could differentiate the major mechanisms
driving cell cholesterol efflux and test both plasma and10 J. Lipid Res. (2021) 62 100065apoB-depleted plasma in order to determine differ-
ences related to species and seasons. The use of apoB-
depleted plasma or isolated HDL as cholesterol
acceptor is an established method for the measurement
of HDL CEC. Indeed, the interferences of apoB-
containing particles in the efflux process are avoided.
Nevertheless, as also suggested by others (40), apoB-
depleted plasma does not resemble the in vivo situa-
tion since both apoB- and apoAI-containing lipopro-
teins are always present in plasma. It is also known that
plasma albumin can act as cholesterol acceptor from
cells (41). We could show, indeed, that plasma CEC was
higher than apoB-depleted plasma CEC in all the
different efflux pathways and bears had a higher
plasma CEC compared with humans. Interestingly,
when testing HDL CEC, by depletion of the plasma
specimen of the apoB-containing particles, bears, both
in summer and winter, showed higher CEC via ABCA1,
the pathway that determines the capacity of plasma
specimens with similar HDL-C to remove cholesterol
from macrophages (44).
Our study should be considered with the following
caveats. The free-ranging brown bears studied were
subadult animals, whereas the absence of arterial
atherosclerosis was previously assessed in adult bears (6).
On average, primiparity occurs at the age of 4.3 years in
brown bears and senescence at age 23. On this scale, a 12-
year-old brown bear equates to a 45–55-year-old human.
Given the absence of even the earliest signs of athero-
sclerosis (fatty streaks) in adult bear (6), we find it
reasonable to infer that it is likely that brown bears have
structural properties of lipoproteins with low athero-
genic profile even when they circulate with high levels
of cholesterol and TGs in apoB100-containing particles.
Moreover, the bears in the current study were 2–3 years
old at time of sampling: thus, circulating high lipids are
already present early in the life, and most likely remain
high in adulthood. All bears were from the same
geographical area. Moreover, our study focused only on
lipoprotein composition and selected lipoprotein func-
tion: other pathways and mechanisms that may also
differ in brown bears and humans (e.g., phenotype of
circulating monocytes, circulating micro-RNA, compo-
sition of arterial PGs, protective inflammatory responses,
hemodynamic differences) might contribute in
reducing atherogenesis in brown bears.
In conclusion, despite high TC and TG levels in apoB-
containing lipoprotein, the brown bear lipoprotein
profile appears to be less atherogenic than that of
humans, thus resulting in a vasculoprotective effect.
This could be associated with the low LDL affinity for
PGs, secondary to their increased TG and PL, and to
their low positive surface charge. In addition, the
higher plasma CEC may further reduce the atheroge-
nicity of the bear lipoprotein profile, by controlling
cholesterol accumulation in the arterial intima and thus
preventing the early stages of atherosclerosis develop-
ment. These atheroprotective and vasculoprotective
mechanisms of the bear lipoprotein profile seem to be
driven by composition- and structure-modulated
functions.Data availability
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